Red Cell Transfusion Threshold Assessment
Guides red cell transfusion decisions using restrictive vs liberal threshold based on clinical context. NICE/BCSH 2015.
Score interpretation
→ Investigate and treat underlying cause; oral/IV iron if deficient; erythropoietin stimulating agents if CKD; B12/folate if deficient; reassess in 2-4 weeks
→ Consider 1 unit pRBC; reassess Hb after 1 unit before further transfusion; single-unit policy; document indication; inform consent; type and screen; blood administration protocol
→ Transfuse; acute haemorrhage: activate Major Haemorrhage Protocol (1:1:1 pRBC:FFP:platelets); haematology input if haematological cause; transfuse to Hb >=7 (or >=8 in ACS/cardiac); patient blood management; document in notes
Interpretation bands for the Transfusion Threshold. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Voxelotor · Haemoglobin S Polymerisation Inhibitor — Sickle Cell Disease
- Sodium Cromoglicate Nasal Spray · Mast Cell Stabiliser — Allergic Rhinitis
- Olopatadine · H1 antihistamine + mast cell stabiliser
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Rituximab (Haematology) · Anti-CD20 Monoclonal Antibody
- Crizanlizumab · P-selectin Inhibitor — Sickle Cell Disease
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.